MYCN and neuroblastoma: Thereby, despite the extensive study of the genomic characteristics of high-risk NB including MYCN-amplified tumors, genomic profiling of MYCN non-amplified NB, including low- and intermediate-risk NB, has been limited.6, 7, 8, 9